highperformr logo

BeyondSpring's Overview

Total employees51
HeadquartersNew York
Founded

BeyondSpring Pharmaceuticals is a global clinical-stage biopharmaceutical company that was focused on the development of innovative immuno-oncology cancer therapies. Its lead asset, Plinabulin, was being developed as a direct anti-cancer agent and for the prevention of chemotherapy-induced neutropenia. The company also had a pipeline of pre-clinical immuno-oncology drug candidates. In December 2023, BeyondSpring Inc. and its subsidiaries filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware. Operations and future development are subject to the outcomes of these proceedings.

Where is BeyondSpring's Headquarters?

HQ Function

Served as the global corporate headquarters, overseeing strategic direction, investor relations, and U.S. clinical development operations before the Chapter 11 bankruptcy filing.

Notable Features:

Located in a prominent downtown Manhattan skyscraper, 28 Liberty Street, offering access to financial and business hubs. Specific internal features are not widely publicized.

Work Culture:

Prior to bankruptcy, likely a fast-paced, results-driven environment typical of clinical-stage biotech companies, with a focus on scientific innovation and achieving clinical milestones. Cross-cultural collaboration between U.S. and China teams was a key aspect. Current work environment is subject to restructuring.

HQ Significance:

The New York HQ provided access to U.S. capital markets, regulatory bodies (FDA), and a talent pool for clinical development and corporate functions. Its operational significance is now fundamentally altered by the bankruptcy proceedings.

Values Reflected in HQ: Prior to bankruptcy, the choice of a global financial center HQ might have reflected ambition, a global outlook, and a commitment to engaging with the international investment community. These aspects are now overshadowed by the current financial restructuring.

Location:

Prior to its Chapter 11 filing, BeyondSpring Pharmaceuticals operated with a global footprint, primarily between the United States and China. Its U.S. operations focused on corporate strategy, financing, investor relations, and clinical development oversight for global trials. Its China operations were crucial for research and development, preclinical studies, and managing clinical trials within the Asia-Pacific region. This dual-country presence aimed to leverage talent and resources from both major pharmaceutical markets. The current extent of global operations is minimal and subject to bankruptcy proceedings.

Street Address:

28 Liberty Street, 39th Floor

City:

New York

State/Province:

NY

Country:

USA

BeyondSpring's Global Presence

Dalian, Liaoning, China

Address: BeyondSpring (Dalian) Pharmaceutical Co., Ltd., No. 2-1, 7th Road, Shuzigang, Ganjingzi District, Dalian, Liaoning Province, China (or similar addresses in Dalian High-Tech Industrial Zone)

To leverage local scientific talent, conduct research and development, manage clinical trials in the Asia-Pacific region, and engage with the Chinese pharmaceutical market and regulatory authorities (NMPA). Activities are likely ceased or heavily curtailed.

Buying Intent Signals for BeyondSpring

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of BeyondSpring

As of April 2025, BeyondSpring' leadership includes:

Dr. Lan Huang - Co-founder, Chairman, and Chief Executive Officer
Richard Brand - Interim Chief Financial Officer (appointed June 2023)

Investors of BeyondSpring

BeyondSpring has been backed by several prominent investors over the years, including:

Decheng Capital
Huagai Capital
WTT Investment Ltd.
HM Capital
Rushton Capital Management

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits2

The period leading up to BeyondSpring's Chapter 11 filing in December 2023 saw significant leadership changes, particularly in key financial and medical roles, amidst clinical trial setbacks and increasing financial pressures.

Departures

Dr. Ramon Mohanlal, Dr. Ramon Mohanlal departed from his role as Chief Medical Officer and EVP of R&D.
Edward Liu, Edward Liu resigned from his position as Chief Financial Officer.

New Appointments:

Richard Brand, Richard Brand was appointed as Interim Chief Financial Officer.

Technology (Tech Stack) used by BeyondSpring

Discover the tools BeyondSpring uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

BeyondSpring Email Formats and Examples

Common email formats for BeyondSpring Pharmaceuticals likely followed standard corporate patterns such as [first_initial][last_name]@beyondspringpharma.com. Given the company's Chapter 11 status, email communication channels are likely inactive or unmonitored for most former employees.

[first_initial][last]@beyondspringpharma.com

Format

lhuang@beyondspringpharma.com

Example

10%

Success rate

News and media

FierceBiotechDecember 8, 2023

BeyondSpring Pharmaceuticals Files for Chapter 11 Bankruptcy After Plinabulin Trials Disappoint

BeyondSpring Pharmaceuticals and its U.S. subsidiaries filed for Chapter 11 bankruptcy protection following clinical trial disappointments for its lead candidate, Plinabulin, and subsequent financial difficulties. The filing aims to facilitate a restructuring or sale of assets....more

BioSpaceDecember 11, 2023

BeyondSpring Pharmaceuticals Seeks Bankruptcy Protection Amidst Financial Struggles

Global biopharmaceutical company BeyondSpring Inc. announced its voluntary petition for Chapter 11 bankruptcy in the U.S. The move comes after challenges with its lead drug candidate Plinabulin and aims to preserve value for stakeholders during a restructuring process....more

Nasdaq / SEC FilingDecember 18, 2023

BeyondSpring Pharmaceuticals' Stock (BYSI) Delisted from Nasdaq

Following its Chapter 11 bankruptcy filing, BeyondSpring Pharmaceuticals' common stock (BYSI) was delisted from the Nasdaq Stock Market. Trading was suspended on December 7, 2023, and Nasdaq subsequently filed a Form 25 to formally delist the securities....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including BeyondSpring, are just a search away.